| 摘要 |
The invention relates to a novel vaccine suitable for enhancing T-cell dependent immunity comprising a T-cell dependent antigen, such as a soluble protein, and an associated adjuvant, the adjuvant being adapted to stimulate a T-cell lymphocyte via the cell surface receptor CD28.
|
